Products
Sutimlimab Biosimilar Monoclonal Antibody (Complement C1s) for Research
Pre-Made Sutimlimab biosimilar, Whole mAb, Anti-C1S Antibody: Anti-EDSPD2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Sutimlimab (INN; development code BIVV009) is a monoclonal antibody that is being investigated for cold agglutinin disease.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-537-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Sutimlimab biosimilar, Whole mAb, Anti-C1S Antibody: Anti-EDSPD2 therapeutic antibody |
| INN Name | Sutimlimab |
| Target | C1S |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Bioverativ;True North Therapeutics |
| Conditions Approved | na |
| Conditions Active | Autoimmune haemolytic anaemia;Idiopathic thrombocytopenic purpura |
| Conditions Discontinued | Bullous pemphigoid;Renal transplant rejection |
| Development Tech | na |
About target - C1S
1. Protein Complement C1s subcomponent
2. Gene C1S
3. Organism Homo sapiens (Human)
Function
C1s B chain is a serine protease that combines with C1q and C1r to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4.
Catalytic activity
Cleavage of Arg-|-Ala bond in complement component C4 to form C4a and C4b, and Lys(or Arg)-|-Lys bond in complement component C2 to form C2a and C2b: the 'classical' pathway C3 convertase.
Activity regulation
Inhibited by SERPING1.
Kinetics
Less efficient than MASP2 in C4 cleavage.
KM=12.3 µM for complement component C2 (at 37 degrees Celsius)
KM=1.9 µM for complement component C4 (at 37 degrees Celsius)
